The average one-year price target for Exact Sciences (NasdaqCM:EXAS) has been revised to $84.57 / share. This is an increase of 18.76% from the prior estimate of $71.21 dated November 7, 2025. The ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Exact Sciences (NASDAQ:EXAS) has been analyzed by 16 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below provides a concise overview ...

We recently published 10 Stocks Beating Wall Street at its Own Game. Exact Sciences Corp. (NASDAQ:EXAS) is one of the best-performing stocks on Wednesday. Exact Sciences climbed to a new two-year high ...

Meridian Funds, managed by ArrowMark Partners, released its “Meridian Growth Fund” fourth-quarter 2025 investor letter. A copy of the same can be downloaded here. U.S. equity markets experienced a ...

Is Exact Sciences (NASDAQ: EXAS) about to go on a sustained run? The medical diagnostics specialist has lagged the market over the trailing-12-month period, but the stock is rebounding. In the past ...

NEW YORK, Jan. 6, 2026 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it has earned the 2026 Gallup Exceptional Workplace ...